5.55
-0.06(-1.07%)
Currency In USD
Previous Close | 5.61 |
Open | 5.61 |
Day High | 5.68 |
Day Low | 5.48 |
52-Week High | 23.48 |
52-Week Low | 5.41 |
Volume | 807,832 |
Average Volume | 1.31M |
Market Cap | 480.49M |
PE | -2.66 |
EPS | -2.09 |
Moving Average 50 Days | 6.32 |
Moving Average 200 Days | 11.75 |
Change | -0.06 |
If you invested $1000 in Kura Oncology, Inc. (KURA) since IPO date, it would be worth $370 as of May 29, 2025 at a share price of $5.55. Whereas If you bought $1000 worth of Kura Oncology, Inc. (KURA) shares 5 years ago, it would be worth $324.75 as of May 29, 2025 at a share price of $5.55.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting
GlobeNewswire Inc.
May 22, 2025 9:30 PM GMT
– Results from KOMET-001 registration-directed trial of ziftomenib in R/R NPM1-m AML patients selected for oral presentation on Monday, June 2nd – – Encore presentation planned at EHA 2025 Congress – – Kura Oncology to host virtual investor event at
Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress
GlobeNewswire Inc.
May 14, 2025 2:00 PM GMT
– Ziftomenib combined with 7+3 in 1L NPM1-m or KMT2A-r AML patients selected for oral presentation on Thursday, June 12th – – Updated dataset to be presented in oral presentation at EHA2025 Congress – SAN DIEGO and TOKYO, May 14, 2025 (GLOBE NEWSWI
Kura Oncology to Participate in Bank of America Securities Healthcare Conference
GlobeNewswire Inc.
May 06, 2025 11:30 AM GMT
SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in B